Bionano Genomics (BNGO) Fundamental Analysis: Revenue, Earnings & Valuation

0.27 / 10

Underperform

The stock displays poor fundamental strength (0.3/10). Encouraging metrics: Profit-MV and Basic earnings per share (YoY growth rate %), offset by weaknesses in PB-ROE and Cash-MV. This profile warrants a guarded stance.

Analysis Checks(6/10)

Profit-MV

Value0.62

Score2/3

Weight-46.13%

1M Return1.48%

Quick ratio

Value1.74

Score2/3

Weight-31.72%

1M Return1.07%

PB-ROE

Value-1.00

Score0/3

Weight172.36%

1M Return-8.01%

Basic earnings per share (YoY growth rate %)

Value94.50

Score2/3

Weight1.83%

1M Return-0.06%

Current assets turnover ratio

Value0.67

Score1/3

Weight-15.81%

1M Return0.57%

Cash-UP

Value-0.13

Score0/3

Weight101.43%

1M Return-4.68%

Diluted earnings per share (YoY growth rate %)

Value94.50

Score2/3

Weight1.37%

1M Return-0.05%

Total assets turnover ratio

Value0.38

Score3/3

Weight-82.03%

1M Return2.88%

Net profit / Total operating revenue (%)

Value-92.59

Score3/3

Weight-51.96%

1M Return1.85%

Cash-MV

Value0.01

Score1/3

Weight50.65%

1M Return-1.93%

Is BNGO undervalued or overvalued?

BNGO scores 0.27/10 on fundamentals and holds a Premium valuation at present. Backed by its -66.15% ROE, -92.59% net margin, -0.50 P/E ratio, 0.30 P/B ratio, and 94.50% earnings growth, these metrics solidify its Underperform investment rating.